11/21
10:21 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $38.00. They now have an "overweight" rating on the stock.
11/19
12:22 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
11/18
08:09 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $49.00 to $51.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $49.00 to $51.00. They now have a "buy" rating on the stock.
11/16
12:08 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/15
05:46 pm
sndx
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation [Yahoo! Finance]
Low
Report
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation [Yahoo! Finance]
11/15
05:29 pm
sndx
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Medium
Report
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
11/12
12:36 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.
11/12
07:00 am
sndx
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
High
Report
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
11/8
06:07 am
sndx
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results [Yahoo! Finance]
Low
Report
Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results [Yahoo! Finance]
11/7
12:32 pm
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $33.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $30.00 to $33.00. They now have a "buy" rating on the stock.
11/6
08:07 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $45.00 to $47.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $45.00 to $47.00. They now have a "buy" rating on the stock.
11/5
07:12 pm
sndx
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/5
04:01 pm
sndx
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
09:04 am
sndx
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 [Yahoo! Finance]
Low
Report
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 [Yahoo! Finance]
11/5
09:01 am
sndx
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
Low
Report
Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024
11/5
09:00 am
sndx
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
Low
Report
Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting
11/5
09:00 am
sndx
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Low
Report
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
11/4
04:19 pm
sndx
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ [Yahoo! Finance]
11/4
04:01 pm
sndx
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
Medium
Report
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
11/1
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/1
07:00 am
sndx
Syndax Announces Participation in November Investor Conferences
Low
Report
Syndax Announces Participation in November Investor Conferences
10/29
07:00 am
sndx
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
Low
Report
Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024
10/24
07:16 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $37.00 price target on the stock.
Low
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $37.00 price target on the stock.
10/14
09:52 am
sndx
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Stifel Nicolaus from $40.00 to $41.00. They now have a "buy" rating on the stock.
Medium
Report
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Stifel Nicolaus from $40.00 to $41.00. They now have a "buy" rating on the stock.
10/4
04:05 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)